A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

Start Date07 Apr 2025

Sponsor / Collaborator

Brown University

[+2]

NCT06725121

/ RecruitingPhase 1/2IIT

Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial

The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
The main questions it aims to answer are:
* How many patients will achieve transplant with this treatment strategy?
* What will the 5-year survival and recurrence-free survival rates be for these patients?
Participants will:
* Undergo a biopsy of the tumor.
* Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months.
* Be referred for a liver transplant and undergo the procedure if deemed eligible and safe.
* If applicable, be followed for five years post-transplant with regular data collection.

Start Date01 Dec 2024

Sponsor / Collaborator

University Health Network

NCT05655949

/ RecruitingPhase 2IIT

A Single Arm Phase 2 Study of Y-90 SIRT in Combination with Durvalumab (MEDI 4736) and Gemcitabine/cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
The specific names of the interventions that will be used are:
* Y-90 (a type of radiation microsphere bead)
* Durvalumab (a type of immunotherapy)
* Gemcitabine (a type of chemotherapy)
* Cisplatin (a type of chemotherapy)

Start Date13 Feb 2024

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

[+3]

100 Clinical Results associated with Yttrium [90Y] chloride

100 Translational Medicine associated with Yttrium [90Y] chloride

100 Patents (Medical) associated with Yttrium [90Y] chloride

4,748

Literatures (Medical) associated with Yttrium [90Y] chloride

01 Jul 2025·Separation and Purification Technology

Highly efficient separation of yttrium from concentrated strontium aqueous solution by novel silica-based HDEHP-impregnating adsorbent

Author: Wu, Hao ; Jiang, Tianjiao ; Zheng, Ningchao ; Zheng, Qi ; Wu, Qiang ; Sun, Jiayu ; Wei, Yuezhou ; Watabe, Hiroshi ; Wu, Yehuizi ; Ning, Shunyan ; Yin, Xiangbiao ; Hamza, Mohammed F. ; Wu, Yan ; Zeng, Deqian ; Wang, Fan

As the primary fission product in spent nuclear fuel being generally filed into the high-level liquid waste, the ⁹⁰Sr recovered from the reprocessed nuclear fuel could be a significant source for producing ⁹⁰Y nuclide (the decay daughter).It presents as one favorable therapeutic radionuclide candidate for radiolabeling of pharmaceuticals in widespread clin. application.Under this situation, a novel silica-based adsorbent (HDEHP/SiO₂-P) was developed for selective separation of Y³⁺ from concentrated Sr²⁺ in aqueous solutionBatch adsorption process was investigated under different parameters of acid type and strength, contact time, temperature, ionic concentration and molar ratio etc.It was confirmed that, the HDEHP/SiO₂-P had highly selective properties toward Y³⁺ over Sr²⁺ in different acidic medium (i.e., hydrochloric, nitric and acetic acid), with maximum adsorption capacity 34.05 mg Y³⁺/g.Sorption isotherms and uptake kinetics, were better fitting for Langmuir monomol. layer adsorption mode and the pseudo-second order (PSORE) kinetic model resp.The sorbent shows high SF_Y/Sr of 1.93 x 10³ even at a Sr-Y molar ratio of 2 x 10³.Moreover, dynamic separation of trace amount of Y³⁺ from the concentrated Sr²⁺ aqueous solution was successfully validated by the column test, in which 100 % Y³⁺ was recovered.The produced eluate is characterized by a sharp elution curve without Sr trailing under high acidic conditions of 6 M HCl.All these results would promisingly promote the application of the developed material and chromatog. approach to facilely obtain the adequate quantities of ⁹⁰Y with required radiochem. purity for its widespread clin. use.

01 May 2025·Journal of Environmental Radioactivity

Bone and head kidney radiation dosimetry for roach from radioactively contaminated reservoirs: Method elaboration and application

Article

Author: Pryakhin, E A ; Akleyev, A V ; Peretykin, A A ; Shishkina, E A ; Tyukhay, M V

To establish causal relationships between radiation exposure and tissue effects, it is necessary to calculate the doses to critical organs and tissues and to evaluate the dose-effect relationship. The tools of non-human biota dosimetry that exist nowadays do not take into account the heterogeneous radionuclide distribution between organs and tissues. In the current study, a computational phantom of the roach body segment was developed based on the assessment of the morphometric parameters of target organs. The spine, ribs and head kidney were considered as target organs for bone and hematological effects of radiation exposure. The dose factors to convert specific activity of incorporated ⁹⁰Sr and ¹³⁷Cs to dose rates in target organs were calculated based on Monte Carlo simulation of electron and photon transport. One Bq/g of ⁹⁰Sr in bone tissue lead to dose rates equal to 1.98, 3.38 and 7.49 μGy/day in the head kidney, ribs and spine, respectively. The accumulation of ¹³⁷Cs in the bones results in bone-specific dose rates that are 3-4 times lower than those at the same concentration of ⁹⁰Sr. The obtained results were used to calculate doses to the roach from two radioactively contaminated waterbodies of Ural region. Maximum doses were typical of vertebra (1.4 ± 0.2 and 27.0 ± 8.3 mGy/day). They were 1.4-3 times higher than doses head kidney and ribs. One can expect more pronounced bone effects of radiation exposure in the vertebral bodies than in the ribs of fish, and they should be considered as separate target organs in the presence of Strontium isotopes in the environment.

01 May 2025·Radiation Physics and Chemistry

Heterogeneity in dose distribution in Yttrium-90 and Holmium-166 microspheres radioembolization of hepatic tumors

Author: De Paiva, E. ; Da Silva, L. P. ; Trombini, H.

Nuclear medicine therapies face challenges in dosimetric control related to the patient′s anatomy, metabolism, and limitations in dose estimation methods.These challenges are amplified by the introduction of new radiopharmaceuticals and technologies, particularly in the field of theranostics.In this work, the spatial dosimetric heterogeneity generated by microspheres used in radioembolization was characterized and compared as a function of radial position in singular conformations and around clusters.The Monte Carlo simulation package PENELOPE 2014 was used to simulate absorbed doses in homogeneous liver tissue generated by the main microspheres available for treatment: glass - ⁹⁰Y, resin - ⁹⁰Y, and PLLA - ¹⁶⁶Ho.It was determined the parameters of Russel′s equation that better describe the absorbed dose per initial activity of this microspheres, updating the constants for ⁹⁰Y, and determining them to ¹⁶⁶Ho.At a radial distance of 0.77 cm from the center of the microspheres, ⁹⁰Y microspheres provide an absorbed dose per initial activity 126 times greater than ¹⁶⁶Ho microspheres.At this same depth, Y-90 absorbed dose generated by glass and resin microspheres shows a maximum difference of 4%.For clusters, an increased level of dose per initial activity was observed in the vicinity of all median clusters (around 340μm diameter).The results of this study highlight the spatial dosimetric heterogeneity and its significant dependence on the choice of microsphere type, emphasizing the considerable impact often neglected in therapeutic planning worldwide.

News (Medical) associated with Yttrium [90Y] chloride

24 Mar 2025

·www.prnewswire.com

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications. Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumors. As we have highlighted recently, we are advancing our lead targeted radiotherapy Actimab-A into a pivotal Phase 2/3 trial for patients with relapsed or refractory acute myeloid leukemia and in the frontline setting in a Phase 1 trial under our CRADA with the NCI. Additionally, we have launched our Actimab-A solid tumor program to combine with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials. As a pioneer in the development of target radiotherapies, we have aggressive plans to expand our clinical pipeline to address indications with high unmet needs. With this supply agreement with Eckert & Ziegler, we will have access to reliable and constant supply of Ac-225 to advance our product development both in the U.S. as well as internationally." "We are happy to contribute to the continuous expansion of indications for Actinium-225, which is significantly being advanced by Actinium Pharmaceuticals," explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. "The progress we have made in our Ac-225 project over the past year marks only the start of our program to address the global shortage of this vital radionuclide." Eckert & Ziegler reliably supplies high-quality Gallium-68, Lutetium-177, Yttrium-90, and Actinium-225 to leading pharmaceutical companies, and research institutions worldwide. With expertise in radioisotope production and global logistics, the company is committed to continuously support the development and delivery of innovative radiopharmaceuticals. About Eckert & Ziegler Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. For more information, please visit: Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiation Therapy

22 Nov 2024

·pipelinereview.com

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany I November 21, 2024 I Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France’s leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. [1] https://seer.cancer.gov/statfacts/html/amyl.html SOURCE: Pentixapharm

Clinical Study

21 Nov 2024

·www.globenewswire.com

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: https://edoc.mdc-berlin.de/id/eprint/24012/1/24012oa.pdf About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France's leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. For more information, please contact: Pentixapharm Holding AGPhillip Eckert, Investor Relationsir@pentixapharm.comTel. +49 30 94893232www.pentixapharm.com [1] https://seer.cancer.gov/statfacts/html/amyl.html

Clinical Study

100 Deals associated with Yttrium [90Y] chloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	Iceland	Eckert & Ziegler Radiopharma GmbH	19 Jan 2006
Diagnostic agents	European Union	Eckert & Ziegler Radiopharma GmbH	19 Jan 2006
Diagnostic agents	Norway	Eckert & Ziegler Radiopharma GmbH	19 Jan 2006
Diagnostic agents	Liechtenstein	Eckert & Ziegler Radiopharma GmbH	19 Jan 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 3	China	ClinChoice Medical (TIANJIN) Co., Ltd.	13 Sep 2021
Hepatocellular Carcinoma	Phase 3	China	Biocompatibles UK Ltd.	13 Sep 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2024	Not Applicable	Unresectable Hepatocellular Carcinoma	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	osqhrmmywx(ozxqsizxnw) = developed in 8 (12.7%) patients and no serious AE was reported msejainbfl (rzlxtkwjeu ) View more	Positive	07 Dec 2024
ESMO_ASIA2024	Not Applicable	Unresectable Hepatocellular Carcinoma	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	szhxuqkffg(hkkteoqotp) = developed in 8 (12.7%) patients and no serious AE was reported forgjytbfz (pyjigjroqt ) View more	Positive	07 Dec 2024
SNMMI2023	Not Applicable	-	-	13C-Methacetin Breath Tyttrium-90 (Radioembolization with yttrium-90-loaded resin microspheres)	opwjscdefd(ghywalnizm) = significant increase after 7 days delspfgfks (asqenryofw ) View more	-	28 Aug 2023
ASTRO2022	Not Applicable	Melanoma	-	Yttrium-90 (90Y) (iWand AÂ® applicator)	garagdhtze(bxairdfcdr) = lmivobaqcw bzggcutrjw (hitodlzkka ) View more	-	01 Nov 2022
TARGET Round Robin sub-study (EANM2022)	Not Applicable	Hepatocellular Carcinoma 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	pqlfstqsss(obhzgzvzuy) = wehdhbtczc hjodyrgkhr (eyqxfxaata ) View more	-	22 Sep 2022
TARGET Round Robin sub-study (EANM2022)	Not Applicable	Hepatocellular Carcinoma 90 Y glass microspheres	20	Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	pqlfstqsss(obhzgzvzuy) = uuppuzsuhj hjodyrgkhr (eyqxfxaata ) View more	-	22 Sep 2022
SNMMI2022	Not Applicable	Hepatocellular Carcinoma	-	Yttrium-90 (90Y-glass radioembolization)	(pbtrdibhwz) = nxjkmscpmq ymnnhkirge (pfyqchhhgd )	-	08 Aug 2022
SNMMI2022	Not Applicable	-	-	Y-90 (Y90 SIR-Spheres)	tzmpcntuhz(cqmhnuzdjn) = dbpdjloycj eynekfzdbf (pzpzebtvat )	-	08 Aug 2022
SNMMI2022	Not Applicable	-	-	Y-90 (TheraSphere)	tzmpcntuhz(cqmhnuzdjn) = xfogphbxgp eynekfzdbf (pzpzebtvat )	-	08 Aug 2022
SNMMI2021	Not Applicable	Liver metastases	35	yttrium 90 (Patients with metastatic liver disease)	sygdnuulje(hzhjkzstjq) = ihnbhojcml ytillruagv (fvhqhrtdaf, 4.9 (IQR 3.9 - 7.1)) View more	Positive	18 May 2021
EANM2020	Not Applicable	-	-	Yttrium-90 (SiPM-based PET/CT)	dhsykeztvc(smkzbnbfzh) = zhjgbytcjh ubojtknaxs (hfwxmqxwfn ) View more	-	18 Sep 2020
EANM2020	Not Applicable	-	-	yttrium-90 (Plastic syringe shield)	sxkojcakdn(mzepxwgeag) = etjsxlglkq dlizxywzku (fvdipkbcam ) View more	-	18 Sep 2020
EANM2020	Not Applicable	-	-	yttrium-90 (High energy tungsten syringe shield)	sxkojcakdn(mzepxwgeag) = cwzplzkcel dlizxywzku (fvdipkbcam ) View more	-	18 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis